NCT04149691 - Safety, Tolerability and Pharmacokinetics of Oral CPL304110, in Adult Subjects With Advanced Solid Malignancies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 19, 2019

Primary Completion Date

June 30, 2024

Study Completion Date

June 30, 2024

Conditions

Gastric CancerBladder CancerSquamous Non-small Cell Lung CancerCholangiocarcinomaSarcomaEndometrial CancerOther Solid Tumours

Interventions

DRUG

CPL304110

CPL304110 is to be administered orally as hard gelatine capsules once daily in 28-day cycles.

Trial Locations (7)

RECRUITING

Uniwersyteckie Centrum Kliniczne w Gdańsku, Gdansk

RECRUITING

BioResearch Group sp. z o.o., Nadarzyn

RECRUITING

SP ZOZ MSWiA z Warmińsko-Mazurskim Centrum Onkologii w Olsztynie, Olsztyn

NOT_YET_RECRUITING

Klinika Onkologii, Europejskie Centrum Zdrowia, Otwock

RECRUITING

Centrum Onkologii - Instytut im. Marii Skłodowskiej-Curie, Warsaw

RECRUITING

Instytut Gruźlicy i Chorób Płuc, Warsaw

NOT_YET_RECRUITING

Wojskowy Instytut Medyczny, Warsaw